Cytodyn Inc (CYDY)

[HyGro]

LL was not even close to Madrigal's drug. LL's 12 week fat reduction (MDFF) was only 16% while Madrigals' was 48% after 16 weeks of treatment.
That's not even close.

Read it and weep -- https://www.globenewswire.com/en/news-release/2022/01/31/2375613/0/en/Positive-Topline-Phase-3-MAESTRO-NAFLD-1-Data-Demonstrate-Resmetirom-was-Safe-Well-Tolerated-and-Provided-Statistically-Significant-Improvements-in-Key-Measures-of-Liver-and-Cardio.html

Even it the LL 700 mg doubles the 350 mg, it is still not close and certainly no "breakthrough" or attractive for any quality BP to want to license it -- it's not competitive with Madrigal and several other leading NASH competitors (Inventiva which got a BTD, Lipocine for men, Viking, etc.).